title: Anti-inflammatory effect of SQC-beta-CD on lipopolysaccharide-induced acute lung injury.
abstract: OBJECTIVE
  Shuang-Qing-Cao (SQC) is a folk Chinese medicinal formula. The therapeutic effects of inclusion complexation of SQC extract in beta-cyclodextrin (SQC-beta-CD) against lipopolysaccharide (LPS)-induced acute lung injury (ALI) were studied in mice.
  
  
  METHODS
  Two protocols were designed for administration of SQC-beta-CD (10 and 20 mg/kg body weight) or DEX (2 mg/kg). According to Protocol A we intraperitoneally injected diluent (saline with 0.5% Tween 80), SQC-beta-CD or DEX respectively into mice 30 min and 3h after LPS challenge. Alternatively, in Protocol B we administered diluent, SQC-beta-CD or DEX 3h before and 30 min after LPS challenge.
  
  
  RESULTS
  The histological results showed that SQC-beta-CD (20 mg/kg) protected mice from LPS-induced ALI such as oedema, haemorrhage, blood vessel and alveolar structural damage. Furthermore, SQC-beta-CD inhibited LPS-increased pulmonary MPO activity and migration of polymorphonuclear neutrophils (PMNs) into bronchoalveolar lavage fluid (BALF). Immunohistochemical experiment demonstrated that SQC-beta-CD decreased inducible nitric oxide synthase (iNOS) expression in lung 24h after LPS administration. Consequently, SQC-beta-CD prevented LPS-induced nitric oxide (NO) release in BALF.
  
  
  CONCLUSIONS
  The results indicated that SQC-beta-CD is greatly effective in inhibiting ALI. The present study indicated that SQC-beta-CD acted as a potential therapeutic reagent for treating ALI.
authors.affiliation: State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.
authors.forename: Qin
authors.initials: Q
authors.lastname: Feng
authors.forename: Yong
authors.initials: Y
authors.lastname: Ren
authors.forename: Yu
authors.initials: Y
authors.lastname: Wang
authors.forename: Hsiaoyen
authors.initials: H
authors.lastname: Ma
authors.forename: Jun
authors.initials: J
authors.lastname: Xu
authors.forename: Chenrong
authors.initials: C
authors.lastname: Zhou
authors.forename: Zhimin
authors.initials: Z
authors.lastname: Yin
authors.forename: Lan
authors.initials: L
authors.lastname: Luo
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D003907:Dexamethasone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D008070:Lipopolysaccharides; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009569:Nitric Oxide / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000187:drug effects / Q000378:metabolism; D010936:Plant Extracts / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D012128:Respiratory Distress Syndrome / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D047392:beta-Cyclodextrins / Q000737:chemistry
chemical_list: D000893:Anti-Inflammatory Agents; D004365:Drugs, Chinese Herbal; D008070:Lipopolysaccharides; D010936:Plant Extracts; D047392:beta-Cyclodextrins; D009569:Nitric Oxide; D003907:Dexamethasone; D052247:Nitric Oxide Synthase Type II; C031215:betadex